Summarized by Daily Strand AI from peer-reviewed source
When a child is diagnosed with B-acute lymphoblastic leukemia, a common type of childhood blood cancer, doctors quickly begin an initial phase of treatment called induction therapy. The goal is to clear out as many cancer cells as possible. However, not every patient responds well to this crucial first round of treatment. Doctors have long searched for a reliable way to predict which children might struggle with standard therapy, which would allow medical teams to adjust treatment plans much earlier.
Recently, researchers discovered that a specific protein called Sema4D might provide this much-needed early warning. By examining the white blood cells of newly diagnosed children before they started therapy, scientists found a striking pattern. Children who failed to respond to their initial leukemia treatment had significantly higher levels of the Sema4D protein on their cells compared to those who responded successfully.
Through their analysis, the researchers pinpointed a specific risk threshold. They found that if more than 18 percent of a patient's sampled cells express this protein, the child is at a significantly higher risk for induction therapy failure. Statistical testing confirmed that elevated Sema4D expression is a strong indicator of a poor treatment response.
This discovery could eventually transform how oncologists manage childhood leukemia. If doctors can use a simple blood test to measure Sema4D levels right at diagnosis, they could identify high-risk patients immediately. These vulnerable children might then receive alternative or more intensive therapies right from the start, improving their chances of survival and optimizing overall treatment decisions.
It is important to note that this research is still in its early stages. The current findings are based on a small clinical group of just 60 patients. Before a Sema4D test becomes a routine tool in cancer clinics, researchers will need to conduct much larger clinical trials to validate the results and ensure the test is universally reliable.
Interested in Oncology?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.